Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study

Vincenzo Mirone, Roberta d'Emmanuele di Villa Bianca, Emma Mitidieri, Ciro Imbimbo, Ferdinando Fusco, Paolo Verze, Dino F. Vitale, Raffaella Sorrentino, Giuseppe Cirino

Research output: Contribution to journalArticle

Abstract

Background: Phosphodiesterase 5 inhibitors (PDE5-Is) are a mainstay in the therapy of erectile dysfunction (ED). The primary end point of clinical efficacy, both in clinical studies and normal practice, is represented by the International Index of Erectile Function (IIEF). Objective: To evaluate if platelet cyclic guanosine monophosphate (cGMP) could represent a valuable marker for PDE5-I activity in ED. Design, setting, and participants: The study enrolled 46 patients with psychogenic, organic, and mixed ED (20-71 yr of age; IIEF score

Original languageEnglish
Pages (from-to)1067-1073
Number of pages7
JournalEuropean Urology
Volume56
Issue number6
DOIs
Publication statusPublished - Dec 2009

Keywords

  • cGMP
  • Erectile dysfunction
  • Platelet
  • Vardenafil
  • VASP

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study'. Together they form a unique fingerprint.

  • Cite this

    Mirone, V., d'Emmanuele di Villa Bianca, R., Mitidieri, E., Imbimbo, C., Fusco, F., Verze, P., Vitale, D. F., Sorrentino, R., & Cirino, G. (2009). Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study. European Urology, 56(6), 1067-1073. https://doi.org/10.1016/j.eururo.2009.09.031